Articles related to DEVICE/DRUG APPROVALS

Gepotidacin demonstrated superiority to nitrofurantoin in the EAGLE-3 trial with a therapeutic success rate of 58.9% versus 44%, while maintaining a manageable side effect profile primarily consisting of gastrointestinal disturbances.

This innovative intrauterine device may allow for improvements in discontinuation rates due to pain and bleeding and in expulsion rates.

“…three drugs were associated with more negative or failed efficacy trials than positive ones…”

Results of multiple clinical trials demonstrate that SYMBRAVO can provide rapid and long-lasting freedom from migraine pain, whether treatment is taken early in the attack while the pain is mild, or later in the attack when the pain may be severe.

Rapid symptom improvement and sustained 4-week benefits distinguish Spravato monotherapy in treatment-resistant depression, with significant MADRS score reductions versus placebo.

Suzetrigine, a newly approved NaV1.8 inhibitor, offers a promising non-opioid alternative for managing moderate-to-severe acute pain, backed by robust clinical trial data.